Filtered By:
Condition: Migraine
Infectious Disease: Herpes
This page shows you your search results in order of date.
Order by Relevance | Date
Total 15 results found since Jan 2013.
The role of food allergy as a provoking factor of migraine
CONCLUSION: We show for the first time the relationship between delayed-type food allergy and redistribution in the microbiome of the oropharynx of patients with migraine and once again confirm the role of delayed-type food allergy as a clinically significant factor influencing the course of migraine (its intensity and chronicity).PMID:37655411 | DOI:10.17116/jnevro202312308156
Source: Herpes - September 1, 2023 Category: Infectious Diseases Authors: I L Naidenova A B Danilov A V Simonova A A Pilipovich E G Filatova Source Type: research
Effect of Disease Severity on Comorbid Conditions in Atopic Dermatitis: Nationwide Registry-Based Investigation in Finnish Adults
Acta Derm Venereol. 2023 Mar 8;103:adv00882. doi: 10.2340/actadv.v103.4447.ABSTRACTThe majority of registry studies on atopic dermatitis include only patients and diagnoses from specialized healthcare. The aim of this retrospective, real-world cohort study was to evaluate the effect of atopic dermatitis severity on comorbidities and total morbidity, with comprehensive data from both primary and specialty healthcare registries covering the entire Finnish adult population. In total, 124,038 patients were identified (median age 46 years; 68% female) and stratified by disease severity. All regression analyses (median follow-up...
Source: Acta Derm Venereol A... - March 8, 2023 Category: Dermatology Authors: Ville Kiiski Liisa Ukkola-Vuoti Johanna Vikkula Martta Ranta Mariann I Lassenius Jaakko Kopra Source Type: research
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
Dupilumab-induced peripheral neuropathy in a patient with severe asthma
The anti –interleukin (IL)-4 receptor, an antibody dupilumab is used in the treatment of severe asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Common adverse events reportedly include injection site reactions, conjunctivitis, headache, and oral herpes. Dr Lee et al1 provided the f irst reported case of very severe chronic inflammatory demyelinating polyradiculoneuropathy that developed 1.5 years after the initiation of dupilumab treatment for atopic dermatitis. Similarly, we have encountered a case of peripheral neuropathy in a patient with severe asthma being treated with du pilumab and wish to...
Source: Annals of Allergy, Asthma and Immunology - April 28, 2022 Category: Allergy & Immunology Authors: Mayuka Yamane, Hiroshi Ohnishi, Kimiko Tsuji, Kazuki Anabuki, Akihito Yokoyama Tags: Correspondence Source Type: research
Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news
New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque psoriasis (P...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Herpes encephalitis complicated by cerebral haemorrhage
Case report A 46-year-old, previously well, right-handed man presented with a 1 week history of headache, vomiting and confusion. On examination his temperature was 38.3°C, Glasgow Coma Scale score was 14/15 (E4V4M6) and he was severely expressively dysphasic. There was no limb weakness. Initial blood tests, including C reactive protein, were normal. Cranial CT revealed a hypodense area in the left anteromedial temporal lobe (figure 1). Microscopy of CSF from a lumbar puncture showed a pleocytosis (390x106/ml, lymphocytes 95%), with no organism. On a working diagnosis of herpes simplex virus (HSV) encephalitis, em...
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 13, 2013 Category: Neurosurgery Authors: Lo, W. B., Wilcock, D. J., Carey, M., Albanese, E. Tags: Immunology (including allergy), HIV/AIDS, Coma and raised intracranial pressure, Epilepsy and seizures, Headache (including migraine), Infection (neurology), Pain (neurology) Neurological pictures Source Type: research
